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Abstract 
Chronic infection with hepatitis C virus (HCV) is one of the main causes of hepatocellular 
carcinoma. However, the molecular mechanisms linking the infection to cancer development remain 
poorly understood. Here we used HCV-infected cells and liver biopsies to study how HCV modulates 
the glutaminolysis pathway, which is known to play an important role in cellular energetics, stress 
defense and neoplastic transformation. Transcript levels of glutaminolytic factors were quantified in 
Huh7.5 cells or primary human hepatocytes infected with the JFH1 HCV strain as well as in biopsies 
of chronic HCV patients. Nutrient deprivation, biochemical analysis and metabolite quantification were 
performed with JFH1 infected Huh7.5 cells. Furthermore, shRNA vectors and small molecule inhibitors 
were used to investigate the dependence of HCV replication on metabolic changes. We show that 
HCV modulates the transcript levels of key enzymes of the glutamine metabolism in vitro and in liver 
biopsies of chronic HCV patients. Consistently, HCV infection increases glutamine utilization and 
dependence. We finally show that inhibiting glutamine metabolism attenuates HCV infection and the 
oxidative stress associated with HCV infection. 
Conclusions: 
Our data suggest that HCV establishes glutamine dependence, which is required for viral 
replication. Importantly, glutamine addiction is also a hallmark of tumor cells. While HCV induces 
glutaminolysis to create an environment favorable for viral replication, it predisposes the cell to 
transformation. Glutaminolytic enzymes may be interesting therapeutic targets for prevention of 
hepatocarcinogenesis in chronic hepatitis C.    
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Introduction 
Over 170 million people are chronically infected with hepatitis C virus (HCV) worldwide, placing 
them at risk to develop chronic liver inflammation and fibrosis and to progress to cirrhosis and 
hepatocellular carcinoma (HCC) on the long term. Incidences of HCV-induced liver disease and 
cancer will remain high in the coming decade albeit recent progress in the development of direct 
antiviral agents (DAA) (1). With new treatments, sustained virological response (SVR) is predicted to 
become attainable for most patients (2). A therapeutically obtained SVR improves inflammation and 
fibrosis and decreases the risk for HCC. However, in up to 12% of SVR patients, fibrosis levels do not 
reverse and even progress to cirrhosis (3). Furthermore, HCC can still occur in SVR patients, even at 
long periods after treatment, and an advanced pretreatment fibrosis stage is considered a risk factor 
(4). Among the risk factors for fibrosis progression in chronic hepatitis C are features of the metabolic 
syndrome including obesity, dyslipidemia, insulin resistance (IR) and type 2 diabetes. Among these, IR 
and steatosis are frequent in patients and suspected – at least partially – to be directly induced by the 
virus (5, 6). However, metabolic fluxes in HCV-infected cells have not been analyzed in detail, despite 
their pivotal role in cellular transformation.  
The predominant nutrient sources for cancer cells are glucose and glutamine. Both provide 
bioenergetics (ATP) and intermediates for macromolecular synthesis. So far only few reports have 
described changes to glucose uptake and utilization in HCV infection, moreover with contradictory 
results (7, 8). Altered glucose utilization with augmented lactate production and glutamine uptake have 
been reported in HCV-infected hepatoma cells (8, 9), but no underlying details have been published. 
Glutamine supports many metabolic functions needed for cell survival, growth and proliferation. In 
particular it serves as precursor for other amino acids, nucleotides and lipids and as substrate for 
oxidative phosphorylation. In addition it is required for glutathione synthesis and redox homeostasis 
(10). Glutaminolysis is initiated by the conversion of glutamine to glutamate, catalyzed by the rate-
limiting enzyme glutaminase (GLS). Glutamate can serve as precursor for nucleic acid and serine 
synthesis, drives the uptake of other amino acids or is further converted by glutamate-dehydrogenase 
or transaminases to α-ketoglutarate (αKG), which enters the TCA cycle. The phenomenon of 
glutamine-driven anaplerosis provides biosynthetic precursors and allows many tumor cells to sustain 
ATP production by providing enough reducing equivalents to the electron transport chain (11). Two 
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human glutaminase genes exist, GLS (GLS1) and GLS2. GLS displays oncogenic activity while the 
potential role of GLS2 in cancer remains less clear (12). Two GLS isoforms have been described, 
termed KGA and GAC, but their respective functional differences remain uncharacterized.  
Given the importance of glutamine in carcinogenesis, we investigated the role of glutaminolysis in 
HCV infection. We show that HCV increases expression of glutaminolytic enzymes, glutamine uptake 
and glutamine utilization in in vitro infected Huh7.5 cell cultures. Transcripts of key glutaminolytic 
genes were also increased by HCV in infected primary human hepatocytes (PHH). Importantly, we 
show using GLS specific pharmacological inhibitors that HCV replication is sensitive to glutaminolysis. 
Furthermore, expression of several glutaminolytic genes increased together with fibrosis stage and 
inflammation grade in HCV-liver biopsies. Our results suggest that HCV stimulates the glutamine 
metabolism, a metabolic adaptation that boosts viral replication and that may play an important role in 
the predisposition to HCC in chronically infected patients.  
 
Experimental procedures 
Cell culture 
Huh7.5 cells were maintained in Dulbecco’s Modified Eagle Medium containing 25 mM glucose, 1X 
GlutaMAX, 100 U/mL penicillin and 100 µg/mL streptomycin (Life Technologies) and 10% FCS 
(Thermo Scientific), in a 5% CO2-normoxia incubator at 37°C. For glucose and glutamine titration and 
deprivation experiments, Huh7.5 cells were cultured in DMEM no glucose, no glutamine  
supplemented or not with 25 mM glucose and 2 mM glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 10% dialyzed FCS (Life Technologies). 
HCVcc production  
The HCV JFH1 strain previously described by Delgrange et al. (13) was in vitro transcribed and 
electroporated into Huh7.5 cells. Supernatants were harvested, filtered (0.45 µm) and used to infect 
naive Huh7.5 cells. Pooled supernatants were quantified using the TCID50 method. 
Glucose/glutamine utilization and lactate production measurements 
Glucose, glutamine and lactate were quantified by calculating the difference in concentration 
between the culture medium after 24h culture. Glucose titration reagent contained 0,1M 
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triethanolamine pH 7.5 (Sigma), 2 mM NADP
+
 (Roche), 2 mM ATP (Sigma), 2 u/ml hexokinase 
(Sigma) and 2 u/ml glucose-6-phosphate dehydrogenase (Roche). Glutamine was quantified using the 
L-Glutamine/Ammonia assay kit (Megazyme), glutamate with Glutamate Assay Kit (Abcam) and 
glutaminase activity with Glutaminase Microplate Assay Kit (Cohesion biosciences). Lactate titration 
reagent contained hydrazine/glycine (0.4/0.5M) pH 9 (Sigma), 2 mM NAD
+
 (Sigma) and 2 u/ml lactate 
dehydrogenase (Sigma). NADH or NADPH production was quantified by measuring the end-point OD 
of reactions at 340 nm. 
Liver biopsies 
Liver biopsies from control (Hodgkin’s lymphoma, n=12) and chronic hepatitis C (n=119) patients 
and paired biopsies from chronic hepatitis C patients before and during α-interferon/ribavirin treatment 
were acquired during routine diagnostic work whenever sufficient material was available. Information 
on HCV genotype was available for 77 patients, 49 were infected with genotype 1 and 28 with 
genotype 2. Biopsies were used under the French IRB “Comité de Protection des Personnes Sud-Est 
287 IV” agreement #11/040 obtained in 2011. Written informed consent had been obtained.  
RT-qPCR 
RNA was extracted from cells with Trizol reagent (Life Technologies). 1 µg of total RNA was 
DNase-treated (Roche) and reverse transcribed (M-MLV RT, Life Technologies). RNA from liver 
biopsy samples was purified (Nucleospin RNA/protein kit, Macherey-Nagel). 350 ng of RNA was 
reverse transcribed (Superscript Vilo enzyme, Life Technologies). Transcript levels of target genes 
were quantified by RT-qPCR using Sybr Green I Master Mix (Roche) on a LightCycler 480 (Roche). 
Glucuronidase beta (GUSB) served as reference gene for the in vitro study and 
phosphomannomutase 1 (PMM1) for liver biopsies. All primers sequences are available upon request. 
For JFH1, specific primers were adapted from the RC1 and RC21 primers (14). 
Statistics 
Statistics were performed with Student’s t test or the non-parametric Mann-Whitney U and 
Wilcoxon signed rank tests and Spearman correlation analysis. p-value *: < 0.05; **: < 0.01; ***: < 
0.001; ****: < 0,0001 
Additional methods are described in the supplementary section. 
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Results 
HCV infection up-regulates several key factors of glutamine metabolism 
Basal transcript levels of glutaminolytic factors were compared in Huh7.5 cells and PHH. MYC is a 
key transcription factor that drives glutamine addiction in cancer cells by inducing the transcription of 
various glutamine transporters such as Solute carrier family 1 member 5 (SLC1A5) and SLC7A5 as 
well as of GLS, the rate-limiting enzyme of glutaminolysis. Overall, transcript levels of these genes 
were lower in PHH compared to Huh7.5 cells, likely due to the transformed background of the 
hepatoma cell line (Figure 1A). Albeit elevated baseline levels of transcripts of glutaminolytic factors in 
Huh7.5 cells, HCV increased mRNA levels of MYC and both glutaminase transporters significantly not 
only in PHH but also in Huh7.5 cells, infected at a multiplicity of infection (MOI) of 5 and 1, 
respectively. (Figure 1B,C). HCV also induced the two GLS isoforms KGA and GAC in Huh7.5 cells, 
while only GLS GAC was found increased in PHH. Both isoforms are associated with carcinogenesis. 
In contrast, HCV did not induce transcript levels of GLS2, the isoform expressed in the liver under 
normal physiological conditions, in Huh7.5 nor in PHH. Induction of glutaminolytic transcripts was not 
observed with UV-irradiated virus (Figure 1C), and induction of MYC and GLS by naïve virus 
confirmed on the protein level in Huh7.5 cells (Figure 1D). In infected cells, MYC accumulated 
particularly in nuclear fractions, indicating activation of its transcriptional activity. In order to test 
whether induction of glutaminolytic factors by the virus is a direct effect, co-localizations were 
performed on infected Huh7.5 cells (MOI 0,1) at 3 days post infection (dpi), using an antibody specific 
to GLS isoforms KGA and GAC. The virus was present in a large majority of cells, but expression 
levels were heterogeneous. GLS expression was overall induced by the virus in the culture, but 
strongly HCV-positive cells did not display the highest GLS staining (Figure 1E), suggesting that GLS 
induction may not be directly mediated by HCV but rather by virus-induced oxidative stress or 
inflammatory processes. GLS induction by HCV was furthermore found to be reversible. Huh7.5 cells 
were infected at an MOI of 0,1 for 4 days and then treated with the DAA sofosbuvir for further 2 days 
(Figure 1F). mRNA levels of MYC, GLS KGA and GAC, SLC1A5 and SLC7A5 were increased in 
cultures 4 dpi, but returned to baseline upon successful elimination of HCV by sofosbuvir treatment, 
demonstrating that the transcriptional induction of these genes is reversible.  
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Glutamine metabolization is increased in HCV-infected cells 
The effect of HCV on glucose and glutamine utilization was assessed. 3 dpi, when the virus had 
spread throughout the culture (Figure 2A), culture medium was changed and harvested 24hrs later to 
quantitate glucose and glutamine. In infected cells, consumption of both nutrients was increased 
(Figure 2B), suggesting that HCV induces glycolysis as well as glutaminolysis. To test the impact of 
nutrient composition of the culture medium on HCV-induced glutamine uptake, mock and infected cells 
were cultured from 3 dpi onwards in conditioned media containing glucose or glutamine only, or the 
combination. Supernatants were harvested 24hrs later, and the procedure repeated on day 4 and 5. 
Supernatants were analyzed by nuclear magnetic resonance (NMR). HCV induced significant changes 
to levels of several amino acids.  However, only glutamine and glutamate levels were changed in 
mock versus infected cells irrespective of the culture media used (Table 1, Figure 2C). Infected cells 
depleted more glutamine compared to mock from the supernatant, while glutamate levels increased, 
pointing to an active glutamate export from infected cells, possibly in exchange for other amino acids. 
In order to ask whether glutamine taken up by infected cells feeds into the TCA cycle, and in order to 
assess the respective contributions of glutaminolysis and glycolysis to the TCA cycle, lactate 
production was quantified. Glucose is the predominant substrate for lactate production. However, 
lactate can also be produced from glutamine via the TCA cycle intermediate malate. 3 dpi cell media 
were replaced with conditioned media containing both glucose and glutamine, glutamine only or 
glucose only and were harvested 24hrs later. In the presence of glucose containing media, HCV 
increased lactate production by 20 to 30% (Figure 2D). When only glutamine was available overall 
lactate production was lower, but HCV increased lactate production by close to 300%, indicating that 
partial glutamine oxidation through the TCA cycle is significantly activated in HCV-infected cells. 
These data were confirmed in a 3 day time course in medium containing glutamine only, where lactate 
production increased over time (Figure 2E).  
 
Glutamine is more essential than glucose for the proliferation of HCV-infected 
cells 
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To estimate the relative importance of glucose and glutamine in HCV infection, proliferation of 
mock and HCV-infected cells was monitored in conditioned media containing or not glucose and 
glutamine. HCV-infected Huh7.5 cells were seeded and cultured in the indicated growth media and 
cell proliferation quantified each day. Proliferation of control cells was overall faster than that of HCV-
infected cells and more sensitive to glucose than to glutamine deprivation. In contrast, proliferation of 
HCV-infected cells was more sensitive to glutamine than to glucose withdrawal, underlining the 
importance of glutamine in HCV infected cells (Figure 3A,B). HCV expression was still detectable 
under all culture conditions 4 days after medium change (Figure 3C,D), suggesting that the differences 
in proliferation were predominantly due to metabolic restraints induced by the virus. Furthermore, the 
effects of glutamine withdrawal on proliferation of both mock and HCV-infected cells could be almost 
completely rescued by αKG supplementation (Figure 3A, B), suggesting that HCV induces 
glutaminolysis in order to maintain TCA cycle activity.  
Glutaminolysis is required for HCV replication 
To investigate the dependence of HCV on glutamine metabolism, Huh7.5 cells were infected and 
culture media changed 4hrs later with control and glutamine-deprived media. Viral RNA was quantified 
by RT-qPCR 3 dpi and standardized to cellular RNA content in order to compensate for effects on cell 
growth (Figure 4A). Glutamine withdrawal from cell culture medium clearly inhibited the establishment 
of an HCV infection by over 60%. Addition of non-essential amino acids (NEAA), glutamate or αKG to 
the no-glutamine medium rescued HCV replication (Figure 4A). This indicates that HCV requires 
glutamine for production of αKG, likely for anaplerotic purposes. To verify the importance of 
glutaminolysis in the HCV life cycle, transcript levels of MYC and GLS were silenced in Huh7.5 cells 
with shRNAs. Knock down efficiencies of the shRNAs were verified the same day the cells were 
seeded for infection.  MYC and GLS transcript levels were found to be reduced by 67% and 71%, 
respectively in comparison to control shRNA (Figure 4B). 3 dpi HCV replication was quantified and 
found to be inhibited by 53 and 38% in shMYC and shGLS cells, respectively, compared to scramble 
control. Silencing of GLS could be partially rescued by addition of αKG. To validate MYC and GLS as 
antiviral targets, the effect of pharmacological small molecule inhibitors on HCV replication was tested. 
The MYC inhibitor 10058-F4 is known to have a potent anti-cancer effect in vitro (15). The GLS 
inhibitors [Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) and CB-839 are 
known to block the catalytic center of GLS. CB-839 is currently under evaluation in a phase I clinical 
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trial for several types of cancers (16, 17). No cell toxicity of these inhibitors was observed on Huh7.5 
cells with the exception of CB-839 where cytotoxicity became detectable at the strongest dose tested 
(Figure 4C). Huh7.5 cells were infected with MOIs of 0,1 and 1, the inhibitors or carrier added 4 hrs 
later and replication quantitated 3 dpi. All three molecules inhibited the establishment of an infection in 
a dose dependent fashion with the strongest effect displayed by CB-839 (Figure 4C). CB-839 
treatment also reduced HCV NS3 and NS5A protein levels at 3 dpi (Figure 4D). To control the 
pharmacological inhibition of GLS activity, intracellular glutamate levels as well as glutaminase activity 
were assessed in the presence of CB-839. HCV increased glutaminase activity in infected cells by ca 
1,5 fold (Figure 4D). This increase was inhibited in a dose dependent manner by CB-839. Intracellular 
glutamate levels were not increased by the virus, possibly due to the important turn over and utilization 
of glutamate for amino acid import/exchange and the TCA cycle, as shown before in Figure 2C and D. 
CB-839, however, decreased intracellular glutamate in a dose dependent fashion (Figure 4D). The 
antiviral effect of CB-839 could be partially reversed by addition of αKG, suggesting that besides an 
increased glutaminolytic flux into the Krebs cycle glutaminase may fulfill additional functions in the viral 
life cycle (Figure 4D). To investigate whether the pharmacological inhibitors of MYC and GLS also 
inhibit an already established infection, Huh7.5 cells were infected and cultured for a minimum of 10 
days. Infected cells were re-seeded, 10058-F4, CB-839 or DMSO carrier added and HCV replication 
quantified 3 days later. Inhibition of MYC had a reproducible, moderate inhibitory effect. Inhibition of 
GLS blocked HCV replication in a dose dependent manner by up to 40% within the 3 day period 
(Figure 4E).  
HCV has previously been shown to augment production of oxidative stress and in particular 
superoxide anions (18).  In addition, glutaminolysis in cancer cells is required for redox homeostasis.  
Therefore the effect of CB-839 on superoxide anion levels in HCV infected cells was assessed.  CB-
839 partially blocked the 2 fold increase of superoxide anions induced by HCV (Figure 4F).  
MYC, SLC7A5 and GLS levels are elevated in chronic hepatitis C patients  
To explore whether glutaminolysis is induced in vivo, MYC, SLC1A5, SLC7A5 and GLS (KGA and 
GAC) transcript levels were quantified by RT-qPCR in liver biopsies from patients with chronic 
hepatitis C (n = 119) diagnosed with genotype 1 or 2, as well as patients with liver complications from 
Hodgkin’s lymphoma as control (n = 12). No difference in the transcript levels of SLC1A5 was 
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detected. However, mRNA levels of MYC, SLC7A5 and both GLS isoforms were significantly elevated 
in the HCV group (Figure 5A). Among the HCV patient cohort, activity grades and fibrosis stages were 
available for 117/119 and 101/119 biopsies, respectively. MYC, SLC1A5 and GLS (KGA and GAC) 
mRNA levels increased together with activity grade and fibrosis stage (Figure 5A). Additional clinical 
data could be obtained for some of the HCV patients: age (for 90/119 patients); body mass index 
(BMI) (65/119); alkaline phosphatase (77/119); aspartate aminotransferase (ASAT) (78/119); alanine 
aminotransferase (ALAT) (78/119); gamma-glutamyltransferase (GGT) (78/119); albumin (67/119).  
Results of association studies are presented in Table 2. Weak but significant positive correlations 
were detected between MYC, SLC1A5, GLS KGA, GLS GAC and GGT and ASAT levels; further 
correlations were found between GLS KGA, GLS GAC and BMI as well as between GLS GAC and 
ALAT levels. Furthermore a tendency for a correlation between MYC, SLC1A5 and GLS KGA mRNA 
and ALAT levels (p-values between 0.0575 and 0.0708) was observed. No difference between the 
transcript levels of all these genes between patients infected with HCV genotype 1 and 2 was 
observed (not shown), suggesting that induction of glutaminolysis is induced in the context of both 
genotypes. To ask whether increases in MYC, SLC7A5 and GLS levels in patients were virus-induced 
and reversible upon antiviral treatment, transcripts of HCV, MYC, SLC1A5, SLC7A5 and GLS were 
quantified in 9 paired biopsy couples obtained from patients before and during/after α-
interferon/ribavirin treatment (Figure 5B). MYC and SLC7A5 were significantly decreased with antiviral 
treatment alongside HCV levels. GLS levels showed a tendency to decrease (p=0.13) and no 
difference in transcript levels was observed for SLC1A5.  
 
Discussion 
The molecular mechanisms involved in the progression from chronic HCV infection to HCC are not 
well established. Here, we report that HCV infection may predispose hepatocytes to liver 
tumorigenesis through alterations of glutamine metabolism (Figure 6). In tumor cells glutamine 
utilization and the subsequent induction of key target genes involved in glutamine uptake and 
oxidation is frequently driven by the transcription factor MYC (19). Induction of MYC expression by 
HCV-induced beta catenin and -Akt signaling has already been reported (20, 21), but we have 
extended this finding to MYC-target genes that drive glutamine metabolism: the two glutamine 
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transporters SLC1A5 and SLC7A5, as well as two cancer-associated isoforms of glutaminase - GLS 
KGA and GAC. Even though basal expression of glutaminolytic factors is elevated in Huh7.5 cells in 
comparison to PHH, HCV still induces a significant additional increase of these factors in this cell line. 
We therefore based our experimental approaches on Huh7.5 cells and corroborated these findings in 
a physiologically appropriate background including experimentally infected PHH and liver biopsies of 
HCV infected patients.  
Interestingly, SLC1A5 and SLC7A5 have been described in the literature to be up-regulated in a 
broad range of human cancers, including HCC (22). Likewise, high expression and activity of GLS 
KGA and GAC in cancer cells have been extensively reported (10, 23). GLS is known to be important 
for liver cancer. Indeed, GLS activity is known to correlate with the volume doubling time of rat 
hepatomas (24). Here, we observed that HCV infection increased the transcripts of both KGA and 
GAC isoforms to a similar extent in Huh7.5 cells, however only the KGA isoform was found induced by 
HCV in PHH, while both KGA and GAC isoforms were induced in patient biopsies. The reasons for 
this discrepant finding are unclear at this stage and warrant further investigation. Transcript levels of 
GLS2, the glutaminase endogenously expressed in the liver, were at the limit of detection in Huh7.5 
cells and not increased by the virus in Huh7.5 cells nor in PHH. In addition, we observed increased 
glutamine consumption in HCV-infected Huh7.5 cells together with an elevation of glucose utilization 
and lactate production. These results are consistent with the recently reported stabilization of hypoxia 
inducible factor 1α, the increase of hexokinase 2 activity and stimulation of aerobic glycolysis in 
infected cells (8, 25). Furthermore, the cancer specific form of pyruvate kinase, PKM2, which mediates 
the final step of glycolysis, has been shown to interact with HCV polymerase NS5B and to be required 
for HCV replication (26, 27). These data, as well as a recent proteomic analysis of HCV-infected cells 
(9), suggest that glycolysis plays a major role in the HCV life cycle. 
A frequent consequence of aerobic glycolysis is the inhibition of glucose-derived pyruvate entry in 
the mitochondria, where the TCA cycle produces precursors for biosynthetic processes such as lipid, 
nucleotide and amino acid synthesis.  Tumor cells are known to compensate for the loss of glucose-
derived TCA cycle intermediates by activating glutaminolysis (10). Our results strongly suggest that 
HCV reprograms metabolism by increasing utilization of glutamine for anaplerotic purposes. However, 
a part of the absorbed glutamine is re-secreted in the form of glutamate, probably in exchange for 
other amino acids. This finding has already been reported in various cancer cells and confirms an 
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important role for the amino acid metabolism in HCV infection (28). The deleterious effects of 
glutamine withdrawal on the growth of HCV-infected cells could be fully rescued by αKG. Increased 
glutaminolysis and TCA cycle activity have been associated with increased respiratory activity and 
production of reactive oxygen species in cancer cells. The glutaminase inhibitor CB-839 partially 
reduced the HCV-induced increase of superoxide anion production in Huh7.5 cells, suggesting that at 
least in part the increase in oxidative stress in infected cells is due to mitochondrial/respiratory activity. 
Therefore it will be interesting to investigate whether glutaminase inhibitors reduce the oxidative and 
inflammatory environment that contributes to fibrosis progression in the infected liver. Furthermore, we 
found that early glutamine withdrawal after HCV infection inhibited viral replication. Again, the reason 
is likely to be a drop in TCA cycle intermediates as the effect could be rescued by αKG 
supplementation, however the rescue was less efficient than rescue in the context of Gln withdrawal or 
GLS silencing for reasons that warrant further investigation.  
It was recently shown that reductive carboxylation of glutamine-derived αKG was the predominant 
source of de novo lipid synthesis in many tumor cells (29-31). Considering the importance of lipids in 
the HCV life cycle (6), reductive carboxylation from glutamine-derived carbons may be activated in 
HCV-infected cells to provide lipids in favor of the HCV life cycle. Further experiments are required to 
verify this hypothesis. In the present study, targeting MYC or GLS, via shRNA or pharmacological 
inhibitors, significantly attenuated HCV replication. Considering the major functions of MYC in the 
promotion of cell growth, many pathways are likely to be deregulated by its inhibition. However, 
targeting GLS more specifically suppresses glutaminolysis, which strengthens the important role of 
this pathway in HCV replication. Interestingly, glutaminase inhibitors have recently also been shown to 
display antiviral activity against adenovirus, herpes simplex virus 1 and influenza A (32), suggesting 
that glutaminase inhibitors may be interesting to develop as general antivirals because they block the 
metabolic requirements for progeny virion production.  
The importance of glutaminolysis in HCV replication in vitro was validated in vivo in HCV liver 
biopsies. MYC, SLC7A5 and both forms of GLS were increased in biopsies of HCV-infected patients 
compared to control liver biopsies derived from Hodgkin’s lymphoma, that are characterized by 
hepatic infiltrations. Transcripts of glutaminolytic factors tended to decrease upon antiviral treatment, 
suggesting that glutaminolysis is at least partially reversible in vivo. Moreover, transcript levels of 
MYC, SLC1A5 and both forms of GLS progressively increased together with fibrosis stage, activity 
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grade, and serum levels of several liver enzymes. These data suggest, that although some direct 
effects of HCV are likely to participate, oxidative stress, inflammation and liver disease may also be 
linked to and amplify the increase of glutaminolysis. The possibility of an indirect induction of 
glutaminolysis by HCV is furthermore supported by our finding that the levels of GLS expression did 
not always correlate with HCV protein levels in in vitro infected Huh7.5 cells. Surprisingly few is known 
so far on the links between glutaminolysis, oxidative stress and immune reactions, however, an 
increase in hepatic glutamine transport has been associated with inflammation in a model of 
endotoxemic rats (33).  In contrast to the other glutaminolytic factors, SLC7A5 levels were already 
higher in HCV patients with low or no liver damage and did not increase further with activity grade, nor 
with the fibrosis stage. Interestingly, SLC7A5 is necessary for mTOR activation, a factor that is 
induced in up to 50% of HCCs (34) and been shown to be required for HCV replication (28, 35, 36).  
Collectively, our data revealed for the first time a link between HCV infection and glutaminolysis. 
We show that viral replication depends on glutaminolysis using genetic and pharmacological 
approaches. Importantly, increased levels of glutaminolysis are likely to provide a metabolic 
environment in infected cells that predisposes to and favors the development of HCC. Thus, 
glutaminolysis inhibitors, currently in clinical trials for cancer treatment, may prove useful for 
prevention of fibrosis progression and cellular transformation particularly in patients at risk of disease 
progression towards HCC despite viral elimination with the newly available DAAs. 
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Figure Legends 
Figure 1. Glutaminolytic factors are increased in HCV-infected cells and return to basal levels 
upon viral clearance 
(A) Expression levels of MYC, SLC1A5, SLC7A5 and GLS isoforms KGA and GAC or GLS2 
transcripts were quantified by RT-qPCR in Huh7.5 cells and primary human hepatocytes (PHH) using 
GUS as housekeeping gene (mean±SEM values of 3 or more independent experiments). (B) HCV 
replication levels at 3 dpi in Huh7.5 cells infected (MOI 1) with native or UV irradiated virus analyzed 
by RTqPCR and immunofluorescence (IF) with an anti-HCV serum (green). PHH infected with HCV at 
an MOI of 5 to 10 and harvested between 3 and 5 dpi (absolute quantification revealed between 4000 
to 9000 HCV genome copies/µg RNA). (C) MYC, SLC1A5, SLC7A5, GLS KGA /GAC and GLS2 
transcript levels were amplified using GUS as housekeeping gene in Huh7.5 cells and PHH. Fold 
changes standardized to mock infection are shown (mean±SEM, n= 2 to 10 independent 
experiments). (D) Total lysates, nuclear and cytoplasmic fractions of HCV infected Huh7.5 cells were 
immunoblotted with -MYC, -PARP, -Tubulin, -GLS, -actin and -core specific antibodies. Protein 
quantification was performed with ImageJ software. Results were standardized to PARP (MYC) or 
actin (GLS) expression and are expressed as fold change between infected and uninfected cells (a 
representative immunoblot is shown; graph: mean±SEM, n=4). (E) Huh7.5 cells were infected with 
HCV (MOI 0.1). 3 dpi, cells were fixed and stained with anti-HCV serum and anti-GLS antibody. 
Representative images are shown, n=4. (F) 4 dpi infected (MOI 0,1) and uninfected Huh7.5 cells were 
treated with 5 µM sofosbuvir (Sofo) or carrier for 2 days. HCV, MYC, SLC1A5, SLC7A5 and GLS 
mRNA levels were quantified by RT-qPCR at 4 and 6 dpi using GUS as housekeeping gene. HCV 
data were standardized to infection at 4 dpi. MYC, SLC1A5, SLC7A5 and GLS were standardized to 
mock-infection (mean±SEM, n=up to 7) (C-F) Statistics: Student t-test. 
Figure 2. HCV infection increases glutamine utilization  
(A–E) Huh7.5 cells were mock- or HCV-infected (MOI 1) for 3 days before cell media change. 24 hrs 
after the cell medium change, cell numbers were counted and supernatants harvested for metabolite 
quantification. Metabolite concentrations were corrected for cell numbers. Grey bars present mock, 
black bars HCV infected cultures. (A) HCV infection was controlled at 3 dpi by IF with an anti-HCV 
serum (green). (B) Glucose and glutamine consumption was measured biochemically in normal 
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medium (25mM glucose, 2mM glutamine) and data were standardized to mock infected cells. 
(mean±SEM, n=4) (C) Supernatants of mock and infected cells cultured in normal medium or 
conditioned media containing only glucose or only glutamine were harvested 3, 4 and 5 dpi and 
subjected to NMR analysis. Glutamine and glutamate concentrations (arbitrary units) were 
standardized for cell numbers. (mean±STD, n=3). (D) Lactate was quantified biochemically in 
supernatants of infected/uninfected cells cultured in the indicated conditioned cell media at 3 dpi. Data 
are standardized to mock infected cells cultured in normal medium (mean±SEM, n=4). (E) Lactate was 
quantified by NMR in supernatants of mock and infected cells cultured in only glutamine containing 
medium at 3, 4 and 5 dpi. Lactate concentrations (arbitrary units) were standardized for cell numbers. 
(mean±SEM, n=3). 
 
Figure 3. Proliferation of HCV-infected cells but not of uninfected cells is highly sensitive to 
glutamine withdrawal 
Huh7.5 cells were infected (MOI 1) and reseeded 5 dpi using the indicated conditioned cell media. Cell 
proliferation was monitored from the day of reseeding onwards (mean±SEM of one representative 
experiment of 4 performed with 6 biological replicates). (A) Cell proliferation count in the presence of 
conditioned media standardized to day 1 of reseeding; αKG (α-ketoglutarate; 2 mM). (B) Cell growth 
depicted in Figure 2A represented as area under curve (AUC) taking day 1 as baseline. (C,D) Viral 
infection at day 4 post-reseeding by IF using an anti-HCV serum and by HCV RTqPCR (standardized 
to replication in control medium).  
 
Figure 4. Glutaminolyis is required for HCV replication 
(A) Huh7.5 cells were infected with HCV (MOI 0.1). After 4 hrs culture media were replaced with 
conditioned media (control, no glutamine (gln), no gln + non-essential amino acids (NEAA), no gln + 
2mM glutamate (glu), no gln + 2mM αKG). Intracellular HCV RNA levels were quantitated 3 dpi and 
standardized to infection in control medium. (B) shCTRL, shMYC and shGLS Huh7.5 cell lines (37, 
38) were controlled for MYC and GLS silencing efficiencies and infected with HCV (MOI 0.1). 2mM 
αKG was added with the virus as indicated. Intracellular HCV RNA levels were measured by RT-qPCR 
3 dpi. (C) Left graph: Viability was assessed in Huh7.5 cells by Neutral Red incorporation after 3 days 
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of treatment with MYC inhibitor 10058-F4 and GLS inhibitors BPTES and CB-839 at the indicated 
concentrations (µM). Middle/Right graphs: Huh7.5 cells were infected with HCV at the indicated MOIs. 
After 4 hrs cells were treated with vehicle (DMSO) or increasing concentrations of 10058-F4 (6.25, 
12.5 and 25 µM), BPTES (1, 3 and 6 µM) and CB-839 (1, 5 and 10 µM). Intracellular HCV RNA levels 
were measured by RT-qPCR 3 dpi. DMSO volumes were the same for each drug condition. (D) 
Glutaminase inhibitor CB-839 was added at the indicated concentrations 4 hrs after infection (MOI 1) 
of Huh7.5 cells. The impact on HCV protein levels (representative western with anti-NS3 and NS5A 
antibodies), intracellular glutaminase activity (U/mg) and intracellular glutamate levels was assessed 
3dpi. In the rightmost graph, 2mM αKG was added together with CB-839 to Huh7.5 cells 4 hrs after 
infection (MOI 1) and HCV replication levels were quantitated by RTqPCR at 3 dpi. (E) Persistently 
infected Huh7.5 cells (>10 days) were treated for 3 days with DMSO, 10058-F4 (12.5 and 25 µM) and 
CB-839 (1, 5 and 10 µM) and HCV replication quantitated by RT-qPCR and standardized to replication 
levels at the moment of addition of drugs. (F) Huh7.5 cells were infected with HCV (MOI 0.1) and 
treated with DMSO or 5 µM CB-839. 3 dpi superoxide anion levels were quantified by FACS using 
dihydroethidium (DHE). A representative FACS histogram is depicted. (A-F) Mean±SEM, n=minimum 
3 experiments performed in triplicate. 
 
Figure 5. Glutaminolytic factors are increased in liver biopsies of chronic hepatitis C patients 
and MYC, and SLC7A5 levels decrease with antiviral treatment 
(A)  Top panel: Transcript levels of MYC, SLC1A5, SLC7A5 and GLS were measured by RT-qPCR in 
liver biopsies of 119 HCV and 12 control patients. Min to max box plots of 2
-∆Cp
 values are shown. 
Statistics: Mann-Whitney U test. Middle and bottom panel: MYC, SLC1A5, SLC7A5 and GLS (KGA 
and GAC) transcript levels were plotted against activity grade (A1-A3) and fibrosis stage (F1-F4) of the 
chronic hepatitis C liver biopsies. Group sizes: Activity A1 n = 18; A2 n = 87; A3 n = 12; Fibrosis F1 n 
= 22; F2 n = 37; F3 n = 32; F4 = 10. Statistics: Mann-Whitney U test. (B) Transcript levels of HCV, 
MYC, SLC1A5, SLC7A5 and GLS were measured in 9 paired biopsies from chronic hepatitis C 
patients before and during/after interferon-α/ribavirin therapy. Results are presented as 2
-∆Cp
 values. 
Statistics: Wilcoxon signed rank test. 
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Figure 6. Glutamine is essential in many aspects of cell metabolism.  
After entering the cell through specific transporters, glutamine (Gln) can be partially oxidized through 
glutaminolysis. The first and rate-limiting step is the conversion of glutamine to glutamate (Glu) by the 
enzyme glutaminase (GLS). Glu can then enter the TCA cycle after being converted to alpha-
ketoglutarate (αKG). Gln is also a major precursor for nucleotide as well as glutathione (GSH) 
synthesis. ATP: adenosine triphosphate; Cit: citrate; Glc: glucose; Lac: lactate; Mal: malate; Pyr: 
pyruvate; 
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Table 1. HCV alters amino acid levels in supernatants of infected cells. 3 dpi, supernatant of mock or infected 
cells was replaced with conditioned growth media (25mM glucose, 2mM glutamine; 25mM glucose; 2mM 
glutamine). 24hr later media were harvested and replaced. The procedure was repeated on day 4 and 5. 
Metabolites in supernatants were quantified by NMR. Values were corrected for metabolite concentration in the 
culture media not exposed to cells. Data (in arbitrary units) present the mean concentration measured days 3 to 
5, corrected for cell density. Tendencies of metabolite concentrations to decrease or increase in infected cells 
are indicated by arrows. p values (Mann-Whitney U) are indicated. Statistically significant changes are marked in 
bold.  
    Glucose/Glutamine Glucose only Glutamine only 
    mock HCV+   p value mock HCV+   p value mock HCV+   p value 
M
e
ta
b
o
li
te
s 
(A
.U
.)
 
Arg -0,096 -0,069   0,2332 -0,208 -0,021   0,0420 -0,437 -1,230 ↓ 0,0017 
Gln -0,564 -0,709 ↓ 0,0041 - -     -5,321 -7,832 ↓ 0,0003 
Glt 0,063 0,508 ↑ 0,0003 0,061 0,234 ↑ 0,0003 0,202 1,771 ↑ 0,0003 
Gly - -     - -     0,320 0,862 ↑ 0,0003 
Ile -0,004 0,049   0,0851 0,187 0,158   0,4263 -0,042 -0,119   0,3311 
His -0,005 -0,024   0,2891 -0,043 0,015   0,0703 0,015 0,034   0,4529 
Met -0,042 0,056 ↑ 0,0003 0,005 0,024   0,0467 -0,217 -0,245   0,6911 
Thr -0,064 0,073 ↑ 0,0469 -0,057 0,189   0,0772 -0,041 -0,280 ↓ 0,0041 
Tyr 0,038 0,050   0,3536 0,048 0,088   0,0849 0,130 0,089   0,5660 
Val -0,095 -0,142   0,0468 -0,213 -0,261   0,1451 -0,343 -0,766 ↓ 0,0023 
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Table 2. Spearman correlation analysis between MYC, SLC1A5, SLC7A5 and GLS (KGA and 
GAC) transcript levels and BMI score, alkaline phosphatase (AP), gamma glutamyl transferase 
(GGT), aspartate and alanine aminotransferase (ASAT, ALAT) and Albumin (Alb) levels and 
patients’ age within the chronic hepatitis C cohort 
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Figure 1. Glutaminolytic factors are increased in HCV-infected cells and return to basal levels upon viral 
clearance  
(A) Expression levels of MYC, SLC1A5, SLC7A5 and GLS isoforms KGA and GAC or GLS2 transcripts were 
quantified by RT-qPCR in Huh7.5 cells and primary human hepatocytes (PHH) using GUS as housekeeping 
gene (mean±SEM values of 3 or more independent experiments). (B) HCV replication levels at 3 dpi in 
Huh7.5 cells infected (MOI 1) with native or UV irradiated virus analyzed by RTqPCR and 
immunofluorescence (IF) with an anti-HCV serum (green). PHH infected with HCV at an MOI of 5 to 10 and 
harvested between 3 and 5 dpi (absolute quantification revealed between 4000 to 9000 HCV genome 
copies/µg RNA). (C) MYC, SLC1A5, SLC7A5, GLS KGA /GAC and GLS2 transcript levels were amplified using 
GUS as housekeeping gene in Huh7.5 cells and PHH. Fold changes standardized to mock infection are shown 
(mean±SEM, n= 2 to 10 independent experiments). (D) Total lysates, nuclear and cytoplasmic fractions of 
HCV infected Huh7.5 cells were immunoblotted with -MYC, -PARP, -Tubulin, -GLS, -actin and -core specific 
antibodies. Protein quantification was performed with ImageJ software. Results were standardized to PARP 
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(MYC) or actin (GLS) expression and are expressed as fold change between infected and uninfected cells (a 
representative immunoblot is shown; graph: mean±SEM, n=4). (E) Huh7.5 cells were infected with HCV 
(MOI 0.1). 3 dpi, cells were fixed and stained with anti-HCV serum and anti-GLS antibody. Representative 
images are shown. (F) At 4 dpi infected (MOI 0,1) and uninfected Huh7.5 cells were treated with 5 µM 
sofosbuvir (Sofo) or carrier for 2 days. HCV, MYC, SLC1A5, SLC7A5 and GLS mRNA levels were quantified by 
RT-qPCR at 4 and 6 dpi using GUS as housekeeping gene. HCV data were standardized to infection at 4 dpi. 
MYC, SLC1A5, SLC7A5 and GLS were standardized to mock-infection (mean±SEM, n=up to 7) (C-F) 
Statistics: Student t-test.  
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Figure 2. HCV infection increases glutamine utilization  
(A–E) Huh7.5 cells were mock- or HCV-infected (MOI 1) for 3 days before cell media change. 24 hrs after 
the cell medium change, cell numbers were counted and supernatants harvested for metabolite 
quantification. Metabolite concentrations were corrected for cell numbers. Grey bars present mock, black 
bars HCV infected cultures. (A) HCV infection was controlled at 3 dpi by IF with an anti-HCV serum (green). 
(B) Glucose and glutamine consumption was measured biochemically in normal medium (25mM glucose, 
2mM glutamine) and data were standardized to mock infected cells. (mean±SEM, n=4) (C) Supernatants of 
mock and infected cells cultured in normal medium or conditioned media containing only glucose or only 
glutamine were harvested 3, 4 and 5 dpi and subjected to NMR analysis. Glutamine and glutamate 
concentrations (arbitrary units) were standardized for cell numbers. (mean±STD, n=3). (D) Lactate was 
quantified biochemically in supernatants of infected/uninfected cells cultured in the indicated conditioned cell 
media at 3 dpi. Data are standardized to mock infected cells cultured in normal medium (mean±SEM, n=4). 
(E) Lactate was quantified by NMR in supernatants of mock and infected cells cultured in only glutamine 
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containing medium at 3, 4 and 5 dpi. Lactate concentrations (arbitrary units) were standardized for cell 
numbers.  (mean±STD, n=3).  
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Figure 3. Proliferation of HCV-infected cells but not of uninfected cells is highly sensitive to glutamine 
withdrawal  
Huh7.5 cells were infected (MOI 1) and reseeded 5 dpi using the indicated conditioned cell media. Cell 
proliferation was monitored from the day of reseeding onwards (mean±SEM of one representative 
experiment of 4 performed with 6 biological replicates). (A) Cell proliferation count in the presence of 
conditioned media standardized to day 1 of reseeding; αKG (α-ketoglutarate; 2 mM). (B) Cell growth 
depicted in Figure 2A represented as area under curve (AUC) taking day 1 as baseline. (C,D) Viral infection 
at day 4 post-reseeding by IF using an anti-HCV serum and by HCV RTqPCR (standardized to replication in 
control medium).  
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Figure 4. Glutaminolyis is required for HCV replication  
(A) Huh7.5 cells were infected with HCV (MOI 0.1). After 4 hrs culture media were replaced with conditioned 
media (control, no glutamine (gln), no gln + non-essential amino acids (NEAA), no gln + 2mM glutamate 
(glu), no gln + 2mM αKG). Intracellular HCV RNA levels were quantitated 3 dpi and standardized to infection 
in control medium. (B) shCTRL, shMYC and shGLS Huh7.5 cell lines (37, 38) were controlled for MYC and 
GLS silencing efficiencies and infected with HCV (MOI 0.1). 2mM αKG was added with the virus as indicated. 
Intracellular HCV RNA levels were measured by RT-qPCR 3 dpi. (C) Left graph: Viability was assessed in 
Huh7.5 cells by Neutral Red incorporation after 3 days of treatment with MYC inhibitor 10058-F4 and GLS 
inhibitors BPTES and CB-839 at the indicated concentrations (µM). Middle/Right graphs: Huh7.5 cells were 
infected with HCV at the indicated MOIs. After 4 hrs cells were treated with vehicle (DMSO) or increasing 
concentrations of 10058-F4 (6.25, 12.5 and 25 µM), BPTES (1, 3 and 6 µM) and CB-839 (1, 5 and 10 µM). 
Intracellular HCV RNA levels were measured by RT-qPCR 3 dpi. DMSO volumes were the same for each drug 
condition. (D) Glutaminase inhibitor CB-839 was added at the indicated concentrations 4 hrs after infection 
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(MOI 1) of Huh7.5 cells. The impact on HCV protein levels (representative western with anti-NS3 and NS5A 
antibodies), intracellular glutaminase activity (U/mg) and intracellular glutamate levels was assessed 3dpi. 
In the rightmost graph, 2mM αKG was added together with CB-839 to Huh7.5 cells 4 hrs after infection (MOI 
1) and HCV replication levels were quantitated by RTqPCR at 3 dpi. (E) Persistently infected Huh7.5 cells 
(>10 days) were treated for 3 days with DMSO, 10058-F4 (12.5 and 25 µM) and CB-839 (1, 5 and 10 µM) 
and HCV replication quantitated by RT-qPCR and standardized to replication levels at the moment of addition 
of drugs. (F) Huh7.5 cells were infected with HCV (MOI 0.1) and treated with DMSO or 5 µM CB-839. 3 dpi 
superoxide anion levels were quantified by FACS using dihydroethidium (DHE). A representative FACS 
histogram is depicted. (A-F) Mean±SEM, n=minimum 3 experiments performed in triplicate.  
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Figure 5. Glutaminolytic factors are increased in liver biopsies of chronic hepatitis C patients and MYC, and 
SLC7A5 levels decrease with antiviral treatment  
(A)  Top panel: Transcript levels of MYC, SLC1A5, SLC7A5 and GLS were measured by RT-qPCR in liver 
biopsies of 119 HCV and 12 control patients. Min to max box plots of 2-∆Cp values are shown. Statistics: 
Mann-Whitney U test. Middle and bottom panel: MYC, SLC1A5, SLC7A5 and GLS (KGA and GAC) transcript 
levels were plotted against activity grade (A1-A3) and fibrosis stage (F1-F4) of the chronic hepatitis C liver 
biopsies. Group sizes: Activity A1 n = 18; A2 n = 87; A3 n = 12; Fibrosis F1 n = 22; F2 n = 37; F3 n = 32; 
F4 = 10. Statistics: Mann-Whitney U test. (B) Transcript levels of HCV, MYC, SLC1A5, SLC7A5 and GLS were 
measured in 9 paired biopsies from chronic hepatitis C patients before and during/after interferon-α/ribavirin 
therapy. Results are presented as 2-∆Cp values. Statistics: Wilcoxon signed rank test.  
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Figure 6. Glutamine is essential in many aspects of cell metabolism.  
After entering the cell through specific transporters, glutamine (Gln) can be partially oxidized through 
glutaminolysis. The first and rate-limiting step is the conversion of glutamine to glutamate (Glu) by the 
enzyme glutaminase (GLS). Glu can then enter the TCA cycle after being converted to alpha-ketoglutarate 
(αKG). Gln is also a major precursor for nucleotide as well as glutathione (GSH) synthesis. ATP: adenosine 
triphosphate; Cit: citrate; Glc: glucose; Lac: lactate; Mal: malate; Pyr: pyruvate;  
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Supplementary Experimental Procedures 
Reagents 
Sofosbuvir (Gilead), BPTES (Atlanchim Pharma), CB-839 (Calithera Biosciences, Inc.), 10058-F4 
(Sigma), doxycycline (Sigma), dimethyl-2-oxoglutarate (Sigma), non-essential amino acids (Life 
Technologies), glutamic acid (Sigma). 
Primary Human Hepatocytes 
Primary human hepatocytes (PHH) were isolated from liver resections and cultivated as described 
previously 1. 
UV-irradiation 
Viral supernatant was irradiated in a Spectrolinker XL1000 (Spectronic Corporation) at 6000 
µJ/cm2.  
Cell proliferation assays 
Proliferation of Huh7.5 cells was quantified by neutral red uptake assay 2. Cell culture medium was 
replaced with a medium containing 40 µg/ml neutral red dye (Sigma), 2 h later cells were washed 
(PBS) and neutral red destain solution (50% ethanol, 1% glacial acetic acid) added. Measure of the 
neutral red extracts at OD 540 nm is an indicator of cell proliferation. Results were confirmed by cell 
counting (Cedex XS analyzer; Roche). 
Lentiviruses 
pGIPZ-shRNA-Crtl and pGIPZ-shRNA-GLS 3 were kindly provided by R.DeBerardinis, UT 
Southwestern, Dallas, United States. pRetrosuper-MYC-shRNA was from Addgene (15662). 
Immunoblotting 
After quantification using BCA Protein Assay Reagent (Thermo Scientific), cell lysates (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP40, 1% protease inhibitors) were denatured 5 min at 
95°C in Laemmli buffer and separated/blotted using SDS-PAGE/nitrocellulose. GLS, MYC, PARP, 
tubulin and β-actin were revealed using a rabbit polyclonal anti-GLS(1) antibody (Sigma  
SAB2105954), the mouse monoclonal 9E10 anti-MYC antibody (Santa Cruz), mouse monoclonals 
against PARP, tubulin and anti-β-actin (Sigma), respectively. Anti-rabbit and anti-mouse antibodies 
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coupled to horseradish peroxidase (Sigma) were used to detect proteins by enhanced 
chemiluminescence (Thermo Pierce).  
Immunofluorescence 
HCV-infected Huh7.5 cells were fixed with methanol/acetone (1:1) and immunostained using a 
patient-derived human anti-serum against HCV, anti-GLS (ab156876, abcam) and an Alexa Fluor 488-
coupled secondary antibody (Life Technologies). Nuclei were stained using DAPI (Sigma). 
NMR 
The 1H NMR experiments were performed at an ambient temperature of 298K on a Bruker Avance 
II spectrometer operating at a resonance frequency of 400 MHz for 1H and equipped with a 5 mm 
ATM BBI probe with z-gradient. Spectra were acquired using a 1D Nuclear Overhauser Enhancement 
Spectroscopy sequence (NOESY) with water presaturation (“noesypr1d” from the Bruker pulse-
program library). Each spectrum was acquired applying 128 transients, a spectral width of 4795.4 Hz, 
a data size of 64 K points, an acquisition time of 6.83 s, a relaxation delay of 6s, a noesy mixing time 
of 20 ms. Additional 2D 1H-1H-TOCSY were applied for peak assignments of the different cell media 
(data not shown).  Spectral processing was performed using the Bruker Topspin software (version 3.1, 
patch level 6). The co-added free induction decays (FIDs) were exponentially weighted with a line 
broadening factor of 0.3 Hz, Fourier-transformed, and manually phase corrected to obtain the 1H NMR 
spectra. A home-written Matlab program (using MATLAB R2012a, Mathworks®) was used for 
bucketing and Probabilistic Quotient Normalization (PQN) of the data. Buckets from the control culture 
media were subtracted from the buckets of the supernatant spectra, and scaled to the number of cells 
in the cell medium at the harvest point. Statistical chemometric analysis was done using PLS-Toolbox 
7.5.2 (Eigenvector Research, Inc.) and Excel 2010 (Microsoft). 
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